Catabasis Completes $69 Million IPO

Cooley advised the underwriters on Catabasis Pharmaceuticals' $69 million initial public offering. Catabasis is a Massachusetts-based clinical-stage biopharmaceutical company focused on the discovery and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker technology platform. The SMART linker technology platform is based on the concept of treating diseases by simultaneously modulating multiple targets in one or more related disease pathways. The company's common stock trades on the Nasdaq Global Market under the symbol "CATB."

Citigroup Capital Markets and Cowen and Co. acted as joint book-running managers for the offering. Oppenheimer & Co. and Wedbush PacGrow acted as co-managers.

Related Contacts
Div Gupta Partner, New York
Darren DeStefano Partner, Reston
Brent Siler Partner, Washington, DC
Wendy Goldstein Partner, New York
Natasha Leskovsek Partner, Washington, DC
Ivor Elrifi Partner, New York
Bill Christiansen Partner, Seattle
Susan Cooper Philpot Retired Partner, San Francisco
Alison Haggerty Associate, New York
Danielle Gershowitz Associate, New York
Phil Mitchell Partner, New York
Megan Arthur Schilling Partner, San Diego